Monopar Therapeutics announces filing of patent protecting MNPR-101

Monopar Therapeutics announced that it has filed a provisional patent application pertaining to the recent advancements and optimizations Monopar has achieved with its MNPR-101 radiopharmaceutical program. The provisional patent titled “Antibody Radioisotope Constructs” that was filed with the United States Patent and Trademark Office outlines the MNPR-101-Zr construct, including variations on the radioisotopes, linkers, and antibody which could enhance the clinical profile of the construct, including properties such as its stability and biodistribution. It also covers the formulations and uses of MNPR-101-Zr, a zirconium-89 imaging radioisotope labeled version of MNPR-101, Monopar’s proprietary first-in-class humanized monoclonal antibody that is highly-selective against the urokinase plasminogen activator receptor. “Filing of this provisional patent application is aimed at further protecting our novel MNPR-101 radiopharmaceutical program,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer. “This patent filing along with our earlier patent filings helps to create a broad portfolio of intellectual property around this program and potential future programs.”